MOUSE MONOCLONAL IGG3 ANTIBODY DETECTING GD3 GANGLIOSIDE - A PHASE-I TRIAL IN PATIENTS WITH MALIGNANT-MELANOMA
MOUSE MONOCLONAL IGG3 ANTIBODY DETECTING GD3 GANGLIOSIDE - A PHASE-I TRIAL IN PATIENTS WITH MALIGNANT-MELANOMA
复制标题
DOI：
10.1073/pnas.82.4.1242
复制
发表时间：
1985-01-01
影响因子：
11.1
通讯作者：
OLD, LJ
中科院分区：
文献类型：
--
作者：
HOUGHTON, AN;MINTZER, D;OLD, LJ
R24是一种IgG 3小鼠单克隆抗体，可识别GD 3，GD 3是黑色素瘤细胞和其他神经外胚层来源细胞表面上的一种突出的神经节苷脂。12例转移性黑色素瘤患者接受了R24治疗，3个剂量水平，8，80或240 mg/m2，超过2周。血清中的峰值抗体水平与剂量相关，范围为< 0.1至62 μ g/ml。炎症反应（荨麻疹、瘙痒、红斑、皮下瘀斑）。80 mg/m2。治疗期间和治疗后的肿瘤活检显示淋巴细胞和肥大细胞浸润，肥大细胞脱粒和补体沉积。副作用轻微，抗组胺药很容易控制。在3例患者中观察到重大肿瘤消退。
R24 is an IgG3 mouse monoclonal antibody that identifies GD3, a prominent ganglioside on the surface of melanoma cells and other cells of neuroectodermal origin. Twelve patients with metastatic melanoma were treated with R24 at 3 dose levels, 8, 80 or 240 mg/m2, over a period of 2 wk. Peak antibody levels in the serum were dose related and ranged from < 0.1 to 62 .mu.g/ml. Inflammatory reactions (urticaria, pruritus, erythema, s.c. ecchymoses) were observed around tumor sites in patients treated at doses .gtoreq. 80 mg/m2. Tumor biopsies during and after treatment showed lymphocyte and mast cell infiltration, mast cell degranulation and complement deposition. Side effects were mild and were readily controlled by antihistamines. Major tumor regression has been observed in 3 patients.